B7-H6/CD3 T-cell engager

B7-H6/CD3 T-cell engager

B7-H6/CD3 T-cell engager

Our B7-H6/CD3 T-cell engager* acts as a bridge that selectively directs the activity of T-cells toward tumor cells that express B7-H6.1

 

Clinical trials (monotherapy and combination therapy): our B7-H6/CD3 T-cell engager is currently being investigated in a Phase I trial as monotherapy and in combination with ezabenlimab (BI 754091)*, a programmed cell death protein-1 (PD-1) inhibitor, in patients with advanced solid tumors that express B7-H6.2

 

Role of B7-H6

B7-H6 is a member of the B7 family of immune receptors, which is expressed in several solid tumor indications, such as CRC, NSCLC, HNSCC, hepatocellular, gastric, and pancreatic carcinoma while no to very little expression can be detected in normal tissues.1,3

About our B7-H6/CD3 T-cell engager

Mechanism of action

Our B7-H6/CD3 T-cell engager simultaneously binds to cluster of differentiation 3 (CD3) expressed on T cells and B7-H6 expressed on tumor cells resulting in formation of a cytolytic synapse and redirection of the cytolytic activity of T cells towards tumor cells that express B7-H6. Consistent with the mode-of-action, the treatment with B7-H6/CD3 T-cell engager in vivo leads to tumor cell apoptosis, local activation and proliferation of T cells, and cytokine secretion in the tumor tissue, converting a non-inflamed (cold) tumor environment into an inflamed (hot) tumor environment.1

T-cell engager mechanism of action1

B7-H6/CD3 T-cell engager MoA
CD3, cluster of differentiation 3.

Watch the T-cell engager mechanism of action animation

Watch the T-cell engager mechanism of action animation

Combination therapy

In humanized CRC mouse models, monotherapy with our B7-H6/CD3 T-cell engager resulted in tumor regression which was associated with local activation and proliferation of T cells, secretion of cytokines, and upregulation of the PD-(L)1 pathway in the tumor tissue; therefore, combination with anti-PD-1 agents (such as ezabenlimab) may further enhance the efficacy of the B7-H6/CD3 T-cell engager.1,4

Clinical development

Our B7-H6/CD3 antibody is currently undergoing clinical investigation in a Phase I study as a monotherapy and in combination with ezabenlimab in patients with advanced solid tumors that express B7-H6.2

B7-H6/CD3 T-cell engager clinical trials

CD3, cluster of differentiation 3; CRC, colorectal cancer.
Trial number Phase Treatment Patient population Status

NCT047522152 (1454.1)

I

B7-H6/CD3 T-cell engager (monotherapy and in combination with ezabenlimab [BI 754091])

Advanced / metastatic CRC OR patients with advanced solid tumors having the B7-H6 marker

Recruiting

Did you find this information useful?

References

1

Hipp S, et al. Presented at: American Association for Cancer Research Annual Meeting 2021; 2021; April 10–15. Philadelphia.

2

ClinicalTrials.gov. NCT04752215. https://clinicaltrials.gov/ct2/show/NCT04752215 (Accessed: July 2021).

3

Brandt C, et al. J Exp Med 2009;206(7):1495–1503.

4

Hipp S, et al. Cancer Res 2021;81(13 Supplement):56. DOI: 10.1158/1538-7445.AM2021-56.

*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.

 

© 2021 Boehringer Ingelheim International GmbH. All rights reserved.

 

Page last updated: August 2021